The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1843-1849

  Sier, Cornelis F M ^b   Stephens, Ross ^c   Bizik, Jozef ^a,d   Mariani, Andrea ^b   Bassan, Marianna ^b   Pedersen, Nina ^a,e   Frigerio, Luigi ^b   Ferrari, Augusto ^b   Danø, Keld ^c   Brünner, Nils ^c   Blasi, Francesco ^b,f  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c FINSEN LABORATORY   (Denmark)

^d CANCER RESEARCH INSTITUTE   (Slovakia)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Dipto di Ric Biol e Tecnologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CELL SURFACE RECEPTOR; TUMOR MARKER; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; AMINO ACID ANALYSIS; AMINO ACID COMPOSITION; ARTICLE; ASCITES; BLOOD LEVEL; CANCER CELL; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; STROMA CELL;

AMINO ACIDS; ASCITIC FLUID; CA-125 ANTIGEN; CHROMATOGRAPHY, AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATORS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; SURVIVAL RATE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032080905     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Fazioli, F., and Blasi, F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci., 15: 25-29, 1994.
2. Blasi, F. uPA, uPAR, PAI-1. Key intersection of proteolytic, adhesive and chemotactic highways? Trends Immunol. Today, 18: 1121-1123, 1997.
3. Danø, K., Andreasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139-266, 1985.
4. Bachmann, F. The plasminogen-plasmin enzyme system. In: R. Hoffman (ed.), Hematology: Basic Principles and Practice, pp. 1232-1242. New York: Churchill Livingstone, 1991.
5. Rønne, E., Pappot, H., Grøndahl-Hansen, J., Høyer-Hansen, G., Plesner, T., Hansen, N. E., and Danø, K. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol., 89: 576-581, 1995.
6. Pedersen, N., Schmitt, M., Rønne, E., Nicoletti, M. I., Høyer-Hansen, G., Conese, M., Giavazzi, R., Danø, K., Kuhn, W., Jänicke, F., and Blasi, F. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J. Clin. Invest., 92: 2160-2167, 1993.
7. Chambers, S. K., Gertz, R. E., Ivins, C. M., and Kacinski, B. M. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptors in ascites of patients with epithelial ovarian cancer. Cancer (Phila.), 75: 1627-1633, 1995.
8. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res., 48: 1348-1349, 1988.
9. Jänicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, W., and Graeff, H. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4: 69-78, 1990.
10. Casslén, B., Gustavsson, B., and Åstedt, B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur. J. Cancer, 27: 1445-1448, 1991.
11. Pedersen, H., Grøndahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Danø, K., and Brünner, N. Urokinase and plasminogen activator inhibitor type I in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
12. Ganesh, S., Sier, C. F. M., Heerding, M. M., Griffioen, G., Lamers, C. B. H. W., and Verspaget, H. W. Urokinase receptor and colorectal cancer survival. Lancet, 344: 401-402, 1994.
13. Grøndahl-Hansen, J., Peters, H. A., Van Putten, W. L. J., Look, M. P., Pappot, H., Rønne, E., Danø, K., Klijn, J. G. M., Brünner, N., and Foekens, J. A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res., 1: 1079-1087, 1995.
14. Cantero, D., Friess, H., Deflorin, J., Zimmermann, A., Bründler, M. A., Korc, M., and Büchler, M. W. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer, 75: 388-395, 1997.
15. Ganesh, S., Sier, C. F. M., Griffioen, G., Vloedgraven, H. J. M., De Boer, A., Welvaart, K., Van de Velde, C. J. H., Van Krieken, J. J. M., Verheijen, J. H., Lamers, C. B. H. W., and Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54: 4065-4071, 1994.
16. Foekens, J. A., Schmitt, M., Van Putten, W. L. J., Peters, H. A., Kramer, M. D., Jänicke, F., and Klijn, J. G. M. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol., 12: 1648-1658, 1994.
17. Heiss, M. M., Allgayer, H., Gruetzner, K. U., Funke, I., Babic, R., Jauch, K. W., and Schildberg, F. W. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat. Med., 1: 1035-1039, 1995.
18. Solomayer, E., F., Diel, I., J., Wallwiener, D., Bode, S., Meyberg, G., Sillem, M., Gollan, C. H., Kramer, M. D., Krainick, U., and Bastert, G. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br. J. Cancer, 76: 812-818, 1997.
19. Stephens, R. W., Pollanen, J., Tapiovaara, H., Leung, K. C., Sim, P., S., Salonen, E. M., Rønne, E., Behrendt, N., Danø, K., and Vaheri, A. Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J. Cell Biol., 108: 1987-1995, 1989.
20. Cubellis, M. V., Wun, T. C., and Blasi, F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J., 9: 1079-1085, 1990.
21. Høyer-Hansen, G., Ploug, M., Behrendt, N., Rønne, E., and Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem., 243: 21-26, 1997.
22. Fazioli, F., Resnati, M., Sidenius, N., Higashimoto, Y., Appella, E., and Blasi, F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J., 16: 7279-7286, 1997.
23. Gyetko, M. R., Chen, G-H., McDonald, R. A., Goodman, R., Huffnagle, G. B., Wilkinson, C. C., Fuller, J. A., and Toews, G. B. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J. Clin. Invest., 97: 1818-1826, 1996.
24. Shapiro, R. L., Duquette, J. G., Roses, D. F., Nunes, I., Harris, M. N., Kamino, H., Wilson, E. L., and Rifkin, D. B. Induction of primary cutaneous melanocytic neoplasms in uPA-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res., 56: 3597-3604, 1996.
25. Rahr, H. B., Sørensen, J. V., Larsen, J. F., Svendsen Jensen, F., and Bredahl, C. Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy. Haemostasis, 25: 248-256, 1995.
26. Casslén, B., Bossmar, T., Lecander, I., and Åstedt, B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur. J. Cancer, 30A: 1302-1309, 1994.
27. Bast, R. C., Klug, T. L., John, S. E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., Zurawski, V. R., and Knapp, R. C. A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 309: 883-887, 1983.
28. 2-terminal domain of the urokinase receptor. FEBS Lett., 288: 233-236, 1991.
29. Ploug, M., Rønne, E., Behrendt, N., Jensen, A. L., Blasi, F., and Danø K. Cellular receptor for urokinase plasminogen activator. J. Biol. Chem., 266: 1926-1933, 1991.
30. 2-terminal amino acid sequence and glycosylation variants. Biol. Chem., 265: 6453-6460, 1990.
31. Masucci, M. T., Pedersen, N., and Blasi, F. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J. Biol. Chem., 266: 8655-8658, 1991.
32. Stephens, R. W., Pedersen, A. N., Nielsen, H. J., Hamers, M. J. A. G., Høyer Hansen, G., Rønne, E., Dybkjær, E., Danø, K., and Brünner, N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin. Chem., 43: 1868-1876, 1997.
33. Lavin, P. T., Knapp, R. C., Malkasian, G., Whitney, C. W., Berek, J. C., and Bast R. C. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet. Gynecol., 69: 223-227, 1987.
34. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
35. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
36. Roldan, A. L, Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Danø, K., Appella, E., and Blasi, F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J., 9: 467-474, 1990.
37. Ehlers, M. R. W., and Riordan, J. F. Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. Biochemistry, 30: 10065-10074, 1991.
38. Solberg H., Rømer, J., Brünner, N., Holm, A., Sidenius, N., Danø, K., and Høyer-Hansen, G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer, 58: 877-881, 1994.
39. Young, T. N., Rodriguez, G. C., Moser, T. L., Bast, R. C., Pizzo, S. V., and Stack, M. S. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am. J. Obstet. Gynecol., 170: 1285-1296, 1994.
40. Schmalfeldt, B., Kuhn, W., Reuning, U., Pache, L., Dettmar, P., Schmitt, M., Jänicke, F., Höfler, H., and Graeff, H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res., 55: 3958-3963, 1995.
41. Ward, B. G., and McGuckin, M. A. Are CASA and CA125 concentrations in peripheral blood sourced from peritoneal fluid in women with pelvic masses? Cancer (Phila.), 73: 1699-1703, 1994.
42. Jardí, M. Inglés-Esteve J., Burgal, M., Azqueta, C., Velasco, F., López-Pedrera, C., Miles, L. A., and Félez, J. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thromb. Haemostasis, 76: 1009-1019, 1996.
43. Ganesh, S., Sier, C. F. M., Heerding, M. M., Van Krieken, J. H. J. M., Griffioen, G., Van de Velde, C. J. H., Verheijen, J. H., Lamers, C. B. H. W., and Verspaget, H. W. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer (Phila.), 77: 1035-1043, 1996.
44. Pedersen, N., Brünner, N., Francis, D., Østerlind, K., Rønrie E., Hoi Hansen, H., Danø, K., and Grøndahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
45. Tuxen, M., Sölétormos, G., and Dombernowsky, P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev., 21: 215-245, 1995.
46. Barber, H. R. K. Tumor markers in ovarian cancer. In: Ovarian Carcinoma: Etiology, Diagnosis, and Treatment, pp. 257-272. New York: Springer-Verlag New York, Inc., 1993.
47. Parker, D., Bradley, C., Bogle, S. M., Lay, J., Masood, M., Hancock, A. K., Naylor, B., and Price, J. J. Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br. J. Obstet. Gynaecol., 101: 888-893, 1994.
48. Nagele, F., Petru, E., Medl, M., Kainz, C., Graf, A. H., and Sevelda, P. Pre-operative CA-125. An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet. Gynecol., 86: 259-264, 1995.
49. Venesmaa, P., Lehtovirta, P., Stenman, U. H., Leminen, A., Forss, M., and Ylikorkala, O. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br. J. Cancer, 70: 1188-1190, 1994.
50. Scholl, S. M., Bascou, C. H., Mosseri, V., Olivares, R., Magdelenat, H., Dorval, T., Palangié, T., Validire, P., Pouillart, P., and Stanley, E. R. Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br. J. Cancer, 69: 342-346, 1994.
51. Sier, C. F. M., Quax, P. H. A., Vloedgraven, H. J. M., Verheijen, J. H., Griffioen, G., Ganesh, S., Lamers, C. B. H. W., and Verspaget, H. W. Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases. Invasion Metastasis, 13: 277-288, 1993.
52. 3 binding to vitronectin. Nature (Lond.), 383: 441-443, 1996.
53. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., and Loskutoff, D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs the urokinase receptor-mediated cell adhesion and release? J. Cell Biol., 134: 1563-1571, 1996.
54. Kjøller, L., Kanse, S. M., Kirkegaard, T., Rodenburg, K. W., Rønne, E., Goodman, S. L., Preissner, K. T., Ossowski, L., and Andreasen, P. A. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res., 232: 420-429, 1997.
55. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res., 53: 140-146, 1993.
56. Brouillet, J. P., Dufour, F., Lemamy, G., Garcia, M., Schlup, N., Grenier, J., Mani, J. C., and Rochefort, H. Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer (Phila.), 79: 2132-2136, 1997.
57. Warwas, M., Hacznynska, H., Gerber, J., and Nowak, M. Cathepsin B-like activity as serum tumour marker in ovarian carcinoma. Eur. J. Clin. Chem. Clin. Biochem., 35: 301-304, 1997.